[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-tumor":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,65,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100449162","evaluation-of-resection-techniques-for-pancreatic-tumors-100449162",false,"NCT05128890","Evaluation of Resection Techniques for Pancreatic Tumors","Inclusion Criteria:\n\n* Patients that have undergone pancreatic or liver resection surgeries from January 2006 until December 2020 at Methodist Dallas Medical Center (MDMC)\n* Patients 18 years old or older\n\nExclusion Criteria:\n\n* Patients that have not undergone pancreatic resection surgeries\n* Patients under 18 years of age","ALL","18 Years",{"count":18,"type":19},431,"ESTIMATED","OBSERVATIONAL","The objective of this study is to compare open and minimally invasive pancreatic and liver resection techniques and analyze the different outcome variables from the clinical standpoint.\n\nThe plan is to investigate patient survival, length of stay, complication rates, operative time, transfusion rate, 30 and 90-day readmission rate, and hospital charges.",[23,24,25],"Surgery","Liver Tumor","Pancreas Tumor","RECRUITING","2026-03-18",{"date":29,"type":30},"2026-03-20","ACTUAL",{"date":32,"type":30},"2016-04-16",{"date":34,"type":19},"2027-04-26",{"name":36,"class":37},"Methodist Health System","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":45,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":38},"100561755","evaluation-of-the-safety-and-effectiveness-of-pringle-method-combined-with-ivc-flow-limiting-and-blocking-method-in-laparoscopic-hepatectomy-based-on-non-restrictive-fluid-therapy-strategy-100561755","NCT06594289","Evaluation of the Safety and Effectiveness of Pringle Method Combined With IVC Flow Limiting and Blocking Method in Laparoscopic Hepatectomy Based on Non-restrictive Fluid Therapy Strategy","Inclusion Criteria:\n\n1. Preoperative Child-Pugh classification of liver function Grade A and grade B;\n2. No contraindications for laparoscopic hepatectomy;\n3. Liver diseases include: primary liver cancer, hepatic hemangioma, intrahepatic bile duct calculus, intrahepatic bile duct cell carcinoma, etc.\n4. Patients voluntarily participate and sign informed consent;\n5. According to the Ban difficulty scoring system of laparoscopic hepatectomy, patients with difficulty score of 5 or more were included; Neoplasms near the hepatic portal; Extensive hepatectomy (3 hepatic segments). Patients aged 18-70 years (including 18-70 years)\n\nExclusion Criteria:\n\n1. Poor liver reserve function, ICG retention rate \\> 15%;\n2. severe heart and lung diseases, unable to tolerate general anesthesia surgery;\n3. Previous history of liver surgery;\n4. More than medium amount of chest and abdominal fluid with clinical symptoms:\n5. hepatic encephalopathy;\n6. having a history of psychotropic drug abuse, unable to quit or having a history of mental disorders;\n7. Patients who have received solid organ transplantation or bone marrow transplantation, or within 2 years before surgery\n8. An active autoimmune disease requiring systemic treatment has occurred;\n9. There is an immune deficiency disease or HIV infection;\n10. Those who were not considered suitable for inclusion by the researchers.\n11. Progression of the disease or toxic side effects or serious adverse events that the subjects could not tolerate before surgery after treatment;\n12. Poor patient compliance, non-cooperation, concealment, false reporting and other phenomena: others\n13. Cases where the principal investigator determines that the research protocol is seriously violated.","70 Years",{"count":47,"type":19},220,"INTERVENTIONAL",[50],"NA","The relevant data of 220 patients undergoing laparoscopic hepatectomy in our hospital were collected. Based on randomization, blindness and inclusion and exclusion criteria, the patients were divided into group A (which included Pringle method + restricted fluid management + vasoactive drug use by anesthesiologists) and group B (which included: Pringle method +IVC flow limiting and blocking method, intraoperative fluid rehydration according to physiological requirements and expected loss, no or less vasoactive drugs used during the operation), and intraoperative and postoperative relevant indicators were compared between the two groups, such as; CVP value, fluctuation range, length of operation, time of liver amputation, total blood loss, amount of liver amputation, amount of blood transfusion, and amount of fluid perfusion. Internal environmental indicators: albumin, alanine aminotransferase, aspartate aminotransferase, γ-gt, total bilirubin, renal function, lactic acid, blood gas analysis (three times during the operation). Postoperative indexes: average length of stay and unplanned reoperation rate. While taking into account the safety, effectiveness and interpretability of statistical results, a new laparoscopic hepatectomy technique based on the optimized CLCVP process was constructed to control intraoperative bleeding and GDFT standardized and streamlined intervention strategy. This is not only an important innovation of the CLVCP concept, but also an important link to accelerate the implementation of laparoscopic liver resection technology in grassroots hospitals, and will significantly improve the quality of medical services, which can bring more accurate and efficient treatment programs to patients.",[24],[54,55],"Liver cancer","Laparoscopic","2024-10-21",{"date":58,"type":30},"2024-10-22",{"date":60,"type":30},"2024-09-15",{"date":62,"type":19},"2026-03-31",{"name":64,"class":37},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":45,"enrollmentInfo":72,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":74,"conditions":75,"keywords":76,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":38},"100556396","exploration-of-noninvasive-differential-diagnosis-of-benign-and-malignant-liver-tumors-100556396","NCT06524557","Exploration of Noninvasive Differential Diagnosis of Benign and Malignant Liver Tumors","Department of Ultrasonic Medicine, The First Affiliated Hospital of Air Force Medical University","Inclusion Criteria:\n\n(1) age 18-70 years; (2) liver examination performed for all patients prior to US-guided liver biopsy or surgery; (3) tumor can be visualized in conventional US; (4) largest tumor sectional area saved in DICOM format for use in later analyses; (5) a histopathological diagnosis made either from US-guided liver biopsy or surgical resection; (6) suitable routine clinical and US data obtained within 7 days of the histopathological diagnosis.\n\nExclusion Criteria:\n\n(1) unavailable pathological diagnosis; (2) liver metastatic tumors; (3) poor quality US images; and (4) a past history of surgical resection, percutaneous local ablation, radiation, transarterial and systemic therapies or liver transplantation.",{"count":73,"type":19},200,"To explore an effective noninvasive method for differential diagnosis of liver tumors.",[24],[77,78,79,80],"liver tumors","benign","malignant","Differential diagnosis","2024-07-23",{"date":83,"type":30},"2024-07-29",{"date":85,"type":30},"2018-01-01",{"date":87,"type":19},"2025-12-30",{"name":89,"class":37},"Xijing Hospital",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":48,"phases":101,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":38},"100552878","ambulatory-surgery-after-hepatectomy-monitoring-by-domomedicine-connected-tools-and-a-dedicated-nurse-100552878","NCT06478810","Ambulatory Surgery After Hepatectomy: Monitoring by Domomedicine Connected Tools and a Dedicated Nurse.","Ambulatory Surgery After Hepatectomy: Piloteasibility Study With Securing of the Post-operative Monitoring by Domomedicine Connected Tools and a Dedicated Nurse.","HEPADOM","Inclusion criteria : - Male or female, 18 to 69 years old\n\n* Indication for a minor laparoscopic hepatectomy (benign or malignant liver tumor, requiring resection of 1 or 2 segments maximum)\n* Membership in a social security system or beneficiary\n* Having given free and informed consent) Exclusion criteria : - Patient living alone and without anyone at home during the first 7 days at home\n* Patient unable to be escorted home by a responsible adult upon discharge\n* Non-French speaking patient\n* Uncompliant patient\n* Patient not reachable by phone\n* Home and convalescence site more than an hour's drive from the Paul Brousse Hospital Hepatobiliary Center\n* Women who have started a pregnancy or are breastfeeding\n* Previous hepatic surgery or supra-mesocolic surgery (exception: cholecystectomy)\n* Previous history of supra-umbilical parietal surgery (hernia\u002Fventricle)\n* Contraindication to laparoscopic approach\n* ASA score \\> 2\n* Cirrhosis (=F4 fibrosis suspected on Fibroscan or biopsy)\n* Coagulation disorder (platelets \\\u003C100 G\u002FL, INR \\>1.4), ongoing anticoagulant or antiaggregant treatment that cannot be suspended\n* Associated extrahepatic surgery (cholecystectomy allowed) or simultaneous radiofrequency destruction\n* Body mass index \\> 35kg\u002Fm2\n* Patient under guardianship, curatorship or safeguard of justice\n* Patient under AME (state medical aid)","69 Years",{"count":100,"type":19},20,[50],"There are public health expectations for the development of outpatient surgery and increased comfort and quality of care for the patient. In this study, we are interested in evaluating the feasibility of an outpatient hepatectomy with a a close and secure follow-up at home: through a connected platform and a follow-up by a nurse. The primary endpoint is the rate of re-hospitalization due to a postoperative complication before Day 30 and the rate of conversion to conventional hospitalization (= early failure of outpatient management). This single-center study will includes prospectively 20 patients requiring liver resection of up to 2 segments. The primary endpoint is the rate of re-hospitalization due to a postoperative complication before Day 30 and the rate of conversion to conventional hospitalization (= early failure of outpatient management).",[24,104],"Hepatectomy",[106,107,108],"Ambulatory surgery","Minor hepatectomy","Domomedicine follow-up","NOT_YET_RECRUITING","2024-06-24",{"date":112,"type":30},"2024-06-27",{"date":114,"type":19},"2024-09-01",{"date":116,"type":19},"2025-12-04",{"name":118,"class":37},"Assistance Publique - Hôpitaux de Paris"]